Creating a 3D model of human heart tissue for drug testing
3D in vitro Human Stem Cell-derived Cardiovascular Tissue Model and Microfluidic Platform for Targeted Preclinical Drug Screening
['FUNDING_OTHER'] · UNIVERSITY OF TEXAS EL PASO · NIH-10907503
This study is creating a special 3D model of heart tissue using stem cells to help understand heart diseases and test new medications more accurately, making it easier for doctors to find the best treatments for patients like you.
Quick facts
| Phase | ['FUNDING_OTHER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF TEXAS EL PASO (nih funded) |
| Locations | 1 site (EL PASO, UNITED STATES) |
| Trial ID | NIH-10907503 on ClinicalTrials.gov |
What this research studies
This research focuses on developing a three-dimensional model of human heart tissue using stem cells to better understand cardiovascular diseases and test new drugs. By utilizing human induced pluripotent stem cells, the researchers aim to create a patient-specific platform that mimics the heart's environment, allowing for more accurate drug screening. The approach includes integrating heart cells with blood vessel-like structures in a microfluidic system, which can simulate the conditions of the human body more effectively than traditional methods. This innovative model seeks to replace inefficient animal testing and provide insights into how drugs affect human heart cells.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals with cardiovascular diseases who may benefit from new drug therapies.
Not a fit: Patients with non-cardiovascular conditions or those who do not have access to the research facility may not receive any benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective and personalized treatments for cardiovascular diseases.
How similar studies have performed: Other research has shown promise in using stem cell-derived models for drug testing, indicating that this approach could be a significant advancement in the field.
Where this research is happening
EL PASO, UNITED STATES
- UNIVERSITY OF TEXAS EL PASO — EL PASO, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: NATIVIDAD-DIAZ, SYLVIA — UNIVERSITY OF TEXAS EL PASO
- Study coordinator: NATIVIDAD-DIAZ, SYLVIA
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Atherosclerotic Cardiovascular Disease